Integrated Advisors Network LLC Purchases 9,454 Shares of IDEXX Laboratories, Inc. $IDXX

Integrated Advisors Network LLC increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2,797.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,792 shares of the company’s stock after buying an additional 9,454 shares during the quarter. Integrated Advisors Network LLC’s holdings in IDEXX Laboratories were worth $5,502,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SHP Wealth Management bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $26,000. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories in the third quarter worth about $26,000. Park Place Capital Corp purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the period. Finally, Wormser Freres Gestion raised its position in IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 47 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Up 0.1%

IDXX traded up $0.41 on Tuesday, hitting $565.39. The company had a trading volume of 184,525 shares, compared to its average volume of 571,344. The stock has a fifty day simple moving average of $555.31 and a 200-day simple moving average of $608.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market capitalization of $44.60 billion, a P/E ratio of 41.75, a P/E/G ratio of 3.05 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52-week low of $506.91 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the business earned $2.91 EPS. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Finally, Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 25th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.